News J&J throws the gauntlet down to AZ with new survival data New survival data from MARIPOSA for Johnson & Johnson's Rybrevant/Lazcluze combination in lung cancer could spell trouble for AstraZeneca.
News EU approves endometrial, lung cancer drugs from GSK and J&J Both GSK and J&J have claimed pivotal approvals for growth-phase oncology therapies in the EU.
News J&J says Rybrevant combo has survival edge over Tagrisso Rybrevant plus Lazcluze extended median OS by more than a year compared to Tagrisso in the MARIPOSA trial in treatment-naive, EGFR-mutated NSCLC.
News J&J's Rybrevant okay challenges Tagrisso in first-line NSCLC AstraZeneca's EGFR inhibitor Tagrisso has become the go-to therapy for EGFR-mutated non-small cell lung cancer (NSCLC), but now has competition from Johnson & Johnson's Rybrevant and La
News 'Trust gap' is holding back AI in healthcare The potential for AI to help tackle bottlenecks in healthcare is being held back by patient scepticism and doctor concerns about bias and liability.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.